Betulinic acid suppresses constitutive and TNFα-induced NF-κB activation and induces apoptosis in human prostate carcinoma PC-3 cells

Molecular Carcinogenesis

Volumn 47, Issue 12, 2008, Pages 964-973

  Rabi, Thangaiyan ^a,b   Shukla, Sanjeev ^a,b   Gupta, Sanjay ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Betulinic acid; I B ; IKK; Prostate cancer; Transcription factor

Indexed keywords

BETULIC ACID; DNA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SERINE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA BINDING; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMAZANS; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; TETRAZOLIUM SALTS; TIME FACTORS; TRANSFECTION; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

BETULA PENDULA;

EID: 56749103942     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20447     Document Type: Article

References (42)

1. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: Balancing life and death - A new approach to cancer therapy. J Clin Invest 2005;115:2625-2632.
2. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-734.
3. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436.
4. Gilmore TD. Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 2006;2:6680-6684.
5. Li X, Stark GR. NFkappaB-dependent signaling pathways. Exp Hematol 2002;30:285-296.
6. Tergaonkar V, Correa RG, Ikawa M, Verma IM. Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity. Nat Cell Biol 2005;7:921-923.
7. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-6947.
8. Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004;6:390-400.
9. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003;91:417-420.
10. Suh J, Payvandi F, Edelstein LC, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52:183-200.
11. Fradet V, Lessard L, Bégin LR, Karakiewicz P, Masson AM, Saad F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10:8460-8464.
12. Lessard L, Karakiewicz PI, Bellon-Gagnon P, et al. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006;12:5741-5745.
13. Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22:2862-2870.
14. Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A. The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2000;18:471-479.
15. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-4197.
16. Pisha E, Chai H, Lee IS, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995;1:1046-1051.
17. Vlietinck AJ, De Bruyne T, Apers S, Pieters LA. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med 1998;64:97-109.
18. Fulda S, Friesen C, Los M, et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997;57:4956-4964.
19. Jeremias I, Steiner HH, Benner A, Debatin KM,Herold-Mende C. Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells. Acta Neurochir (Wien) 2004;146:721-729.
20. Mayaux JF, Bousseau A, Pauwels R, et al. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci USA 1994;91:3564-3568.
21. Honda T, Liby KT, Su X, et al. Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorg Med Chem Lett 2006;16:6306-6309.
22. Tan Y, Yu R, Pezzuto JM. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 2003;9:2866-2875.
23. Zuco V, Supino R, Righetti SC, et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 2002;175:17-25.
24. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by betulinic acid. Neoplasia 2005;7:162-170.
25. Selzer E, Pimentel E, Wacheck V, et al. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 2000;114:935-940.
26. Fulda S, Jeremias I, Debatin KM. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004;23:7611-7620.
27. Takada Y, Aggarwal BB. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: Abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 2003;171:3278-3286.
28. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007;67:2816-2823.
29. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: Correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 2004;10:3169-3178.
30. Sun L, Carpenter G. Epidermal growth factor activation of NF-kappaB ismediated through IkappaBalpha degradation and intracellular free calcium. Oncogene 1998;16:2095-2102.
31. Baglin I, Poumaroux A, Nour M, et al. New ursolic and betulinic derivatives as potential cytotoxic agents. J Enzyme Inhib Med Chem 2003;18:111-117.
32. Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 2001;262: 154-169.
33. Kessler JH, Mullauer FB, de Roo GM, Medema JP. Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett 2007;251:132-145.
34. Udeani GO, Zhao GM, Geun Shin Y, et al. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm Drug Dispos 1999;20:379-383.
35. Chen F, Castranova V. Nuclear Factor-kappaB, an unappreciated tumor suppressor. Cancer Res 2007;67:11093-11098.
36. Shumway SD, Miyamoto S. A mechanistic insight into a proteasome- independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells. Biochem J 2004;380:173-180.
37. Meyer S, Kohler NG, Joly A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett 1997;413:354-358.
38. Eiznhamer DA, Xu ZQ. Betulinic acid: A promising anticancer candidate. IDrugs 2004;7:359-373.
39. Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, Bours V. Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999;59:811-815.
40. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, Hayakawa M, Nakamura H. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J. Urol 1999;161:674-679.
41. Gasparian AV, Yao YJ, Kowalczyk D, et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115:141-151.
42. Kasperczyk H, La Ferla-Brühl K, Westhoff MA, et al. Betulinic acid as new activator of NF-kappaB: Molecular mechanisms and implications for cancer therapy. Oncogene 2005;24:6945-6956.